Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2014
At a glance
- Drugs Sitagliptin (Primary) ; Glipizide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Feb 2014 Results published in the Drugs and Aging.
- 05 Nov 2010 New trial record.